Delayed Treatment with AMPA, but Not NMDA, Antagonists Reduces Neocortical Infarction
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
We tested the abilities of two potent non- N-methyl-d-aspartate (non-NMDA) glutamate antagonists [2,3-dihydroxy-6-nitro-7-sulfamoylbenzo( F)quinoxaline (NBQX)] and [1-(4-aminophenyl)-4-methyl-7,8-methylene-dioxy-5 H-2,3-benzodiazepine hydrochloride (GYKI 52466)] to reduce neocortical infarction following 2 h of transient middle cerebral artery occlusion in a hypertensive stroke model in the rat and compared these effects against, and in combination with, a potent NMDA antagonist [(+)-5-methyl-10,11-dihydro-5 H-dibenzo-[ a,d]cyclohepten-5,10-amine maleate (MK-801)]. In Expt. 1, an already established cytoprotective dose of Na+-NBQX (30 mg/kg i.p. × 3) was compared with saline (1 ml), the NMDA antagonist MK-801 (1 mg/kg i.p. × 3), and a combination of the same doses of both NBQX and MK-801. Initial doses were delayed to 90 min following occlusion with subsequent injections at the time of reperfusion and 30 min following reperfusion. Saline-treated rats sustained 181 ± 32 mm 3 (n = 15) of neocortical infarction (mean ± SD). This was significantly reduced by NBQX to 137 ± 25 mm 3 (n = 15, p < 0.05) of damage. Neither MK-801 (170 ± 33 mm 3; n = 11) nor the combination of MK-801 and NBQX (169 ± 20 mm 3; n = 6) proved to be cytoprotective when given with a 90-min delay. In Expt. 2, NBQX (30 mg/kg) was dissolved (6 mg/ml) in 5% dextrose and compared with both saline and dextrose (1.2 ml) i.v. infusions given over a 4-h period starting 1 h after occlusion. Saline-treated rats had a mean infarct of 183 ± 27 mm 3 (n = 6), dextrose-treated had 200 ± 30 mm 3 (n = 9), while for NBQX-treated rats it was reduced to 129 ± 60 mm 3 (n = 10, p < 0.05). Intravenous NBQX precipitated into the renal tubules, causing nephrotoxicity. In Expt. 3, rats were given either saline (1 ml i.p.) or GYKI 52466 (10 mg/kg i.p.) at 30 and 90 min following occlusion and at 30, 90, and 150 min following reperfusion. Saline-treated rats sustained 187 ± 27 mm 3 of neocortical infarction (n = 7), while those treated with GYKI 52466 were protected, with 139 ± 38 mm 3 of infarction (n = 7, p < 0.05). A clinically useful role for α-amino-3-hydroxy-5-methyl-4-isoxazole propionate antagonists in embolic stroke is envisaged if nontoxic drugs can be developed, since cerebroprotection was achieved with delayed treatment with both of these lead compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a Neuroprotectant for Cerebral Ischemia
Sheardown, M. J., Nielsen, E. Ø., Hansen, A. J., Jacobsen, P., & Honoré, T. (1990) · Science · doi:10.1126/science.2154034 · Cited by 1,138
Iino, M., Ozawa, S., & Tsuzuki, K. (1990) · The Journal of Physiology · doi:10.1113/jphysiol.1990.sp018060 · Cited by 497
Buchan, A. M., Li, H., Cho, S., & Pulsinelli, W. A. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90314-j · Cited by 255
Self-citationProtection against ischemic hippocampal CAI damage in the rat with a new non-NMDA antagonist, NBQX
Diemer, N. H., Jørgensen, M. B., Johansen, F. F., Sheardown, M., & Honoré, T. (1992) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1992.tb08052.x · Cited by 106
Cited by
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
“The efficacy of these compounds in a variety of preclinical models of neuronal injury is more robust than that of the NMDA receptor antagonists (Gill, 1994), perhaps with a longer therapeutic window (Xue et al., 1994; Hoyte et al., 2004).”
BackgroundIschemic Cell Death in Brain Neurons
Lipton, P. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1431 · Cited by 3,043
Neuroprotection for ischemic stroke: Past, present and future
Ginsberg, M. D. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.007 · Cited by 779
Liu, Y., Wong, T. P., Aarts, M., Rooyakkers, A., Liu, L., Lai, T. W., Wu, D. C., Lu, J., Tymianski, M., Craig, A. M., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0116-07.2007 · Cited by 773
“8A), which was in line with previous reports (Xue et al., 1994; Margaill et al., 1996).”
ResultThe Role of Excitotoxicity in Neurodegenerative Disease
Doble, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00042-4 · Cited by 723
Neuropharmacology of AMPA and kainate receptors
Bleakman, D., & Lodge, D. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00139-7 · Cited by 363
Obrenovitch, T. P., & Urenjak, J. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(96)00049-4 · Cited by 307
Neuroprotective effect of γ-glutamylethylamide (theanine) on cerebral infarction in mice
Egashira, N., Hayakawa, K., Mishima, K., Kimura, H., Iwasaki, K., & Fujiwara, M. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.03.046 · Cited by 80
Theanine prevents memory impairment induced by repeated cerebral ischemia in rats
Egashira, N., Ishigami, N., Pu, F., Mishima, K., Iwasaki, K., Orito, K., Oishi, R., & Fujiwara, M. (2008) · Phytotherapy Research · doi:10.1002/ptr.2261 · Cited by 40
Metadata
- Authors
- Xue, D., Huang, Z.-G., Barnes, K., Lesiuk, H. J., Smith, K. E., & Buchan, A. M.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 1994-03
- Volume
- 14
- Issue
- 2
- Pages
- 251-261
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W2001198148
- Cited by
- 177
- References
- 4
- FWCI
- 16.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.